Business
Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia
Intranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal Model Enhanced Effect of Mg2+ is the Core Patented Technology of
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"Intranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal Model Enhanced Effect of Mg2+ is the Core Patented Technology of TNX-1900 for Migraine TNX-2900 Orphan Drug Designated Product for Prader-Willi Syndrome Also Contains Mg2+ Issued Patents Expected to Provide Exclusivity Until 2036 CHATHAM, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced the publication of a paper, entitled \"Impact of Magnesium on Oxytocin Receptor Function,\" in the journal Pharmaceutics, that described results from a research team led by Professor David Yeomans1. The paper includes data showing the enhancing effects of magnesium (Mg2+) on the activity of intranasal oxytocin in an animal model of craniofacial pain. The Mg2+ enhanced formulation of intranasal oxytocin is the basis for the Company’s TNX-19002 drug candidate in development to prevent migraine headaches in chronic migraineurs, and TNX-29002 which is in development to treat hyperphagia (over-eating) in adolescent and young adult patients with Prader-Willi syndrome. Professor Yeomans was the scientific founder of Trigemina, Inc. from which Tonix acquired rights to the Mg2+enhanced oxytocin technology. Professor Yeomans is a consultant to Tonix and the research described in the paper was funded in part by Tonix. “This new paper further evidences the important role Mg2+ plays in the effect of oxytocin on pain reduction both in vitro and in vivo in an animal model of head pain,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Prior to this work, studies of intranasal oxytocin on pain yielded inconsistent results because the analgesic effect of oxytocin decreased with higher doses, a phenomenon called ‘high dose inhibition’ or colloquially, as an ‘inverted U’ shaped dose response. Professor Yeomans and his team have shown that adding Mg2+ to intranasal oxytocin reduces or eliminates the ‘high dose inhibition’, such that analgesia increases with higher doses of oxytocin. Consequently, we expect that the Mg2+ enhanced formulation of intranasal oxytocin in TNX-1900 and TNX-2900 may provide consistent effects to the extent that the Mg2+ component of the formulation reduces or eliminates the high dose inhibition and may also allow for using hi...